Bevacizumab-induced pulmonary cystic disease

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Bevacizumab is an angiogenesis inhibitor used in treating various cancers, including metastatic endometrial adenocarcinoma.
• Its mechanism involves impeding tumor growth and enhancing chemotherapy delivery.
• The association between Bevacizumab and cystic lung disease is not well-established.

Observation:

• A 73-year-old woman with metastatic endometrial adenocarcinoma developed worsening respiratory symptoms post-Bevacizumab chemotherapy.
• Chest CT scans revealed the transformation of metastatic lesions into cystic formations.
• Extensive evaluation led to a diagnosis of pulmonary cystic disease secondary to Bevacizumab.

Findings:

• This case presents a rare instance of secondary pulmonary cystic disease.
• The patient's metastatic lesions converted into cystic structures after Bevacizumab treatment.
• Bevacizumab-induced pulmonary cystic disease is an uncommon but significant adverse event.

Implications:

• Recognizing rare side effects of targeted immunotherapies like Bevacizumab is crucial for patient management.
• Further research is needed to elucidate the mechanisms underlying Bevacizumab-induced pulmonary cystic disease.
• This case underscores the importance of vigilant monitoring for atypical treatment complications.